ESR1 and neoplasm: These reports have connected key drivers and tumor subtype e.g., TP53 and PIK3CA mutations with estrogen receptor (ER) negative and positive tumors, respectively, and defined how specific mutations impact prognosis12–14, providing opportunities for patient stratification and novel therapies.